arrow
P

Peter A. Fasching

University Hospital Erlangen
H指数:121
被引数:7.9万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

SERENA-6 visual patient-reported outcomes and safety: camizestrant for emerging ESR1m advanced breast cancer during first-line endocrine-based therapy

SERENA-6视觉患者报告结局与安全性:卡米昔司rant用于新发ESR1m晚期乳腺癌的一线内分泌治疗

2026-07-240
OAAI
Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial

在激素受体阳性晚期乳腺癌一线治疗期间,于ESR1突变出现但疾病进展前转换至卡米泽斯特rant(SERENA-6):一项双盲、安慰剂对照、随机III期试验的扩展分析

2026-07-130
PRE
Prenatal Alcohol Exposure Predicts Academic Outcomes from Childhood to Adolescence: A Prospective Longitudinal Study Based on Meconium Ethyl Glucuronide

产前酒精暴露预测儿童期至青少年期的学业结果:一项基于胎粪乙基葡萄糖苷酸的前瞻性纵向研究

2026-05-070
OAAI
Chemotherapy-Induced Nausea and Vomiting in Early Breast Cancer Patients Receiving Adjuvant Chemotherapy With Fluorouracil, Epirubicin, Cyclophosphamide Followed by Docetaxel Versus an Anthracycline-Free Regimen With Docetaxel, Cyclophosphamide—Results From a Randomized Clinical Trial
2026-04-290
OAAI
Clinicopathologic and molecular predictors of survival in BRCA-deficient tubo-ovarian high-grade serous carcinoma

BRCA缺陷性输卵管卵巢高级别浆液性癌的生存临床病理及分子预测因子

2026-04-010
OAAI
Distant disease-free survival as a surrogate endpoint for overall survival in randomised trials of neoadjuvant therapy for early breast cancer: a pooled analysis of GBG and AGO-B Study Group trials

远处无病生存期作为早期乳腺癌新辅助治疗随机试验中总生存期的替代终点:GBG和AGO-B研究组试验的合并分析

2025-11-240
PRE
Study Protocol of SURVIVE HERoes (NCT06643585): Trastuzumab Deruxtecan for molecular relapse in HER2+/ Low early breast cancer with ctDNA positivity after primary therapy

SURVIVE HERoes研究方案(NCT06643585):曲妥珠单抗德鲁替康用于HER2阳性/低表达早期乳腺癌在一线治疗后出现分子复发且ctDNA阳性的患者

2025-11-190
PRE
Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival☆

HR阳性/HER2阴性早期乳腺癌患者的辅助瑞博西lib联合非甾体类芳香化酶抑制剂治疗:NATALEE试验5年随访的有效性结局及更新后的总生存期☆

2025-10-170
OAAI
AGO Breast Commission recommendations for the surgical therapy of breast cancer: Working Group on Gynecologic Cancers (AGO) update 2025

AGO乳腺癌委员会关于乳腺癌手术治疗的建议:妇科肿瘤工作组(AGO)2025年更新

2025-09-170
PREAI
Prognostic impact of the choice of chemotherapy after first-line CDK4/6 inhibitor therapy in patients with metastatic hormone receptor-positive, HER2-negative breast cancer

在接受一线CDK4/6抑制剂治疗后,转移性激素受体阳性、HER2阴性乳腺癌患者选择化疗方案的预后影响

2025-08-050
OA
Real-world utilization of aromatase inhibitors, tamoxifen, and ovarian function suppression in premenopausal patients with early hormone receptor-positive, HER2-negative breast cancer with increased recurrence risk

绝经前早期激素受体阳性、HER2阴性且复发风险增加的乳腺癌患者中,芳香化酶抑制剂、他莫昔芬和卵巢功能抑制的实际情况应用。

BREAST
IF7.9
2025-06-010
OAAI
Conditional progression-free survival in patients with metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with first-line ribociclib and endocrine therapy: real-world data from the RIBANNA study

在接受一线瑞博西尼(ribociclib)和内分泌治疗的患者中,激素受体阳性、人表皮生长因子受体2阴性转移性乳腺癌患者的条件无进展生存:RIBANNA研究真实世界数据

2025-06-010
PRE
Real-world risk of recurrence and treatment outcomes with adjuvant endocrine therapy in patients with stage II-III HR+/HER2-early breast cancer

真实世界中HR+/HER2-早期乳腺癌患者接受辅助内分泌治疗的复发风险和治疗结局

BREAST
IF7.9
2025-06-010
OAAI
Effects of pregnancy on breast cancer immunology: immune biomarker and TIL quantification

妊娠对乳腺癌免疫学的影响:免疫生物标志物和TIL量化

2025-05-140
OA
Improving quality of care for cancer patients through oncological second opinions in a Comprehensive Cancer Center: adherence to second-opinion therapy recommendations

通过肿瘤学二次会诊改善综合癌症中心癌症患者护理质量:对二次会诊治疗建议的依从性

2025-04-020
OA